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The purpose of these studies was to test whether pentoxifylline, a drug that can inhibit the 
production and action of cytokines hypothesized to be endogenous pyrogens (for example, 
interleukin 1 and tumor necrosis factor [TNF]), is antipyretic. We also tested the effects of 
pentoxifylline on plasma activities of interleukin 6 (IL 6) and TNF in response to an injection of a 
fever-inducing dose of lipopolysaccharide (LPS). Our results showed that a high dose of 
pentoxifylline (ZOO mg/kg) caused hypothermia in control rats and blocked LPS fever, while a 
low dose (50 mg/kg) did not have these effects. Injection of the high dose of pentoxifylline in 
control rats caused a rise in plasma IL 6 but not in plasma TNF. However, the peak levels of 
plasma IL 6 and TNF activities following an injection of LPS were significantly reduced by 
pretreatment with pentoxifylline. Overall, the data are consistent with the hypothesis that 
pentoxifylline is an antipyretic drug, which may act at least in part by inhibiting the secretion of 
pyrogenic cytokines. 
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Pentoxifylline is a methyl xanthine derivative that 
has been used in the clinical treatment of vascular 
disorders to reduce blood viscosity and to increase 
erythrocyte deformability. ‘J Pentoxifylline also has been 
shown to suppress the production of lipopolysaccharide 
(LPS) induced biological3 and immunological4 tumor 
necrosis factor (TNF) activities and to inhibit the 
inflammatory action of interleukin 1 (IL 1) and TNF on 
neutrophil function.’ TNF has many biological effects, 
including causing hemorrhagic necrosis of tumors6,7 and 
cachexia during infection and cancer,*-” and inducing 
septic shock.g,123’3 Injection of TNF results in fever, and 
many review articles include TNF as an endogenous 
mediator of fever (i.e. an endogenous pyrogen).14915 
However, it has been shown that injection of antiserum 
to TNF enhances LPS fever rather then suppressing it in 
the rat,16 which indicates that TNF may be an endoge- 
nous cryogen or antipyretic rather than a pyrogen in 
LPS fever in this species. In the rabbit, anti-TNF has 
been reported both to block LPS feverI and to leave it 
unaltered.18 It has been reported that TNF can stimu- 
late the release of interleukin 6 (IL 6), a cytokine that 
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not only plays an important role in production of 
antibodies’g320 and acute phase proteins,21V22 but is also 
another putative endogenous pyrogen.23‘25 IL 6 causes 
prostaglandin-dependent fever upon injection into rats, 
and IL 6 concentration increases markedly in the 
plasma and cerebrospinal fluid (CSF) of LPS-injected 
rats.25 
Based on the previously reported effects of pentoxi- 
fylline on the production and action of cytokines thought 
to be endogenous pyrogens, we hypothesized that pentox- 
ifylline would have antipyretic properties, attenuating 
LPS fever in the rat. In this study, we tested this 
hypothesis and, in addition, determined the effects of 
pentoxifylline on plasma activities of IL 6 and TNF in 
response to the injection of fever-inducing doses of LPS. 
RESULTS 
Eflects of Pentoxifylline on Body Temperature 
and LPS Fever 
The purpose of this experiment was to assess the 
antipyretic properties of pentoxifylline. Rats were in- 
jected intraperitoneally (IP) at time 0 with saline or one 
of two doses of pentoxifylline (50 mg/kg or 200 mg/kg). 
At time 60 min post-injection the rats were then injected 
IP with saline (Fig. 1) or 10 pg LPS/kg (Fig. 2). The 
initial temperature increases during the first hour in the 
saline/saline and saline/LPS groups are a nonspecific 
effect usually seen following injection of any substance 
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Figure 1. Effects of pentoxifylline on core tempera- 
ture of rats. 
The first IP injection (either saline or pentoxifylline) 
occurred at time 0 and the second IP injection (saline) 
occurred at 60 min. Temperatures at time 0 for the 
three groups were not significantly different from each 
other and averaged 37.3% n, sample size. 




IP in the rat. However, in none of the groups injected 
with pentoxifylline was there an initial rise in body 
temperature following the injection at time 0. As shown 
in Fig. 1, the injection of 50 mg/kg pentoxifylline had 
little effect on normal body temperature, whereas the 
injection of 200 mg/kg pentoxifylline caused hypother- 
mia (-- 1.3%) for about 2 hr after the injection, As 
shown in Fig. 2, in the group injected with saline 
followed by 10 pug LPS/kg, the temperature began to 
rise at approximately 150 min, reaching a first peak 
(-1.4%) at about 210 min and a second peak (-1YC) 
at 300 to 330 min. In the group injected with 50 mg 
pentoxifylline/kg followed by LPS, the febrile response 
to LPS was similar to that seen in the saline/LPS group. 
In the group injected with 200 mg pentoxifylline/kg 
followed by LPS, the temperature decreased immedi- 
ately following the injection of pentoxifylline, reaching a 
nadir (- 1.2%) at approximately 90 min, returned to 
the base line at about 210 min, and remained at the base 
line up to 420 min. There was a significant difference 
(p < 0.05, analysis of variance [ANOVA]) when we 
compared the mean changes in body temperature at 180 
to 420 min in the three groups (designated Saline/LPS, 
Pen. SO/LPS, and Pen. 2OO/LPS). A comparison of 
Pen. 2OO/LPS group by Fisher’s least significant differ- 
ence method showed that the Pen. 2OO/LPS group had a 
significantly lower value (p < 0.05) than the other two 
groups. 
In order to separate the effects of pentoxifylline on 
the LPS fever from the effects of pentoxifylline itself, we 
generated Fig. 3 by subtracting, for each time, the mean 
temperatures of the rats injected with saline or pentoxi- 
fylline and then saline (data from Fig. 1) from the mean 
temperatures of rats injected with saline or pentoxifyl- 
line and then LPS (data from Fig. 2). Figure 3 shows 
that the febrile responses after injection of LPS in the 
rats that were previously treated with saline or 50 mg 
pentoxifylline/kg were similar. However, despite the 
fact that the body temperature of the rats injected with 
200 mg/kg pentoxifylline had returned to normal by 
about 180 min following this injection (Fig. l), there 
was no febrile response after injection of LPS in the 
---o--- Saline/ LPS n=6 
e Pen. 50mgikgi LPS n=6 
--&-- Pen. 200mglkgl LPS n=6 
Figure 2. Effects of pentoxifylline on the core temper- 
ature rewonse of rats to LPS. . 
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The first IP injection (either saline or pentoxifylline) 
Time (min) 
occurred at time 0 and the second IP injection (LPS) 
Pen. LPS occurred at 60 min. Temperatures at time 0 for the 
or three groups were not significantly different from each 
Saline other and averaged 37.3”C. n, sample size. 
LeMay, Vander, Kluger CYTOKINE, Vol. 2, No. 4 (July 1990: 300-306) 
(Saline/ LPS) - (Saline/ Saline) 
(Pen. 50mgikgi LPS) - (Pen. 50mgikg’ Salme) 
Ine 
Figure 3. Effects of pentoxifylline on LPS-induced 
fever independent of the effects of pentoxifylline itself. 








group that had previously been treated with 200 mg 
pentoxifylline/kg. 
Eflects of Pentoxifylline on the Plasma IL 6 and 
TNF Activities During the LPS Fever 
In these experiments, rats were injected IP at time 0 
with. saline’.or one of two doses of pentoxifylline (50 
mg/kg or 200 mg/kg). Sixty minutes later, the rats were 
injected IP with saline or 10 /*g LPS/kg, and at either 
120 min or 240 min, blood was removed for measure- 
ment of the plasma activities of both IL 6 and TNF. 
The 2-hr data for plasma IL 6 activity are shown in 
Fig. 4. The groups injected with saline/saline or with 50 
mg pentoxifylline/kg and saline showed low levels of 
plasma IL 6 activity (11 + 5 U/mL and 150 I 35 
U/mL). There was a significant difference (p < 0.05, 
ANOVA) when we compared the plasma IL 6 activities 
in the three groups (Saline/saline, Pen. 50/saline, and 
Saline Pen. 50 mgl kg Pen. 200 mg / kg 
Treatment at time zero 
Figure 4. Effects of pentoxifylline alone or pentoxifylline and LPS on 
plasma IL 6 activity in rats. 
Animals were injected with pentoxifylline (either 50 mg/kg or 200 
mg/kg) or saline at time 0 and then with either LPS (IO pg/kg) or 
saline 60 min later. Blood was taken at 120 min. Sample size is 
indicated in parentheses. 
The mean temperatures of the rats injected with saline 
or pentoxifylline and then saline (Fig. 1) were sub- 
tracted for each time from the mean temperatures of 
rats injected with saline or pentoxifylline and then 
LPS (Fig. 2). 
Pen. 200/saline). The plasma IL 6 activity in the group 
treated with 200 mg pentoxifylline/kg and saline 
(17,029 + 8,735 U/mL) was significantly greater 
(p < 0.05, Fisher’s test) than the activity in the saline/ 
saline group or the Pen. 50/saline group. LPS caused a 
large increase in IL 6 in all three groups. Although the 
level of IL 6 activity (43,759 * 22,325 U/mL) in the 
group that was injected with 200 mg pentoxifylline/kg 
and LPS was nearly twice as great as the level of IL 6 
activity in the saline/LPS group (27,248 f 11,243 
U/mL) or in the Pen. SO/LPS group (23,494 + 11,258 
U/mL), there was no statistical difference among these 
three groups (p > 0.65, ANOVA). 
The 4-hr data for plasma IL 6 activity are shown in 
Fig. 5. The groups injected with saline/saline or with 50 
mg pentoxifylline/kg and saline showed low levels of 
plasma IL 6 activity (91 +- 54 U/mL and 34 + 17 
U/mL). The plasma IL 6 activity in the group treated 
with 200 mg pentoxifylline/kg and saline (1,387 t 818 
U/mL) tended to be greater than that of the other two 
groups, but this difference was not statistically signifi- 
cant (p r 0.09, ANOVA). In all three groups receiving 
LPS, there was an increase in plasma IL 6 activity and 
pentoxifylline tended to cause a dose-dependent attenu- 
ation of the IL 6 rise, although there were no significant 
differences (p > 0.08, ANOVA). However, the level of 
IL 6 activity in the group that was injected with 200 mg 
pentoxifylline/kg and LPS (98,653 rt 31,038 U/mL) 
was significantly lower (p c 0.05) by Fisher’s least 
significant difference method than the activity in the 
group injected with saline and LPS (436,175 -t 170,903 
U/mL) or the group injected with 50 mg pentoxifyl- 
line/kg and LPS (249,385 s 30,499 U/mL). 
The 2-hr and 4-hr data for plasma TNF activity are 
shown in Fig. 6. Plasma TNF was not detectable in the 
groups injected with saline and saline, 50 mg pentoxifyl- 
line/kg and saline, or 200 mg pentoxifylline/kg and 
saline at either of these sampling times. In contrast, in 
all three groups receiving LPS there was a marked 
increase in TNF activity in the 2-hr plasma sample, but 
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Figure 5. Effects of pentoxifylline alone or pentoxifylline and LPS on 
plasma IL 6 activity in rats. 
Animals were injected with pentoxifylline (either 50 mg/kg or 200 
mg/kg) or saline at time 0 and then with LPS (10 rg/kg) or saline 60 
min later. Blood was taken at 240 min. Sample size is indicated in 
parentheses. Note that the scale of the Y axis is tenfold greater than 
Fig. 4. 
pentoxifylline caused a dose-dependent attenuation of 
the TNF rise (p < 0.03, ANOVA). The 2-hr plasma 
TNF activity in the group treated with 200 mg pentoxi- 
fylline/kg and LPS (498 2 321 U/mL) was signifi- 
cantly lower (p < 0.05, Fisher’s test) than the activity in 
the group injected with saline and LPS (5,264 t 1,325 
U/mL) or the group injected with 50 mg pentoxifyl- 
line/kg and LPS (2,974 i- 615 U/mL). The 4-hr plasma 
TNF activities in all groups receiving LPS were much 
lower than those seen at 2 hr, but even at these very low 
levels, there was a dose-dependent attenuation of the 
TNF rise by pentoxifylline (p < 0.04, ANOVA), the 
Sample at 240 nun 
a 1 
Saline Pen. 50 mg/kg Pen. 200 mg / kg 
Treatment at time zero 
Figure 6. Effects of pentoxifylline alone or pentoxifylline and LPS on 
plasma TNF activity in rats. 
Animals were injected with pentoxifylline (either 50 mg/kg or 200 
mg/kg) or saline at time 0 and then with either LPS (10 pg/kg) or 
saline 60 min later. Blood was taken at either 120 min or 240 min. 
Sample size is indicated in parentheses. 
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values being 264 k 19 U/mL for the saline group, 67 I 
67 U/mL for the pentoxifylline 50 mg/kg group, and 
undetectable for the pentoxifylline 200 mg/kg group. 
DISCUSSION 
These data demonstrate that a high dose of pentoxi- 
fylline (200 mg/kg) blocks LPS fever, while a low dose 
(50 mg/kg) has no effect. However, although the high 
dose of pentoxifylline completely blocked the rise in 
body temperature due to LPS, this might be the result of 
effects of the drug not specifically related to the path- 
ways by which LPS induces fever. For example, it was 
consistently noted that injection of this dose of pentoxi- 
fylline caused the rats to appear dazed or tranquilized. 
Their eyes were partially closed and inspirations were 
deeper. The rats would respond to noise or handling, but 
when returned to their cages showed little exploratory 
behavior. The rats would remain still, but did not appear 
to be resting. Their forelimbs were extended and their 
heads were tilted upwards. This extended posture adopted 
by the rats might dissipate more heat than the normal 
huddled posture of rats. In addition, it has been reported 
that pentoxifylline is a vasodilator,26 which may also 
contribute to the hypothermia observed with the high 
dose. Pentoxifylline has been reported to stimulate the 
synthesis of prostacyclin; however, it had no effects on 
the plasma concentration of prostaglandin E,,26 a puta- 
tive neuro-mediator for the regulation of body tempera- 
ture. 
It has been reported that pentoxifylline can also 
stimulate the release of interferon (Y,~~ a putative endog- 
enous pyrogen. 28 Since we did not observe a rise in body 
temperature following the injection of pentoxifylline, we 
do not think that any possible rise in interferon cz activity 
was high enough to cause fever in our experiments. 
Injection of 200 mg/kg pentoxifylline led to an 
elevation in plasma IL 6 at 2 hr following the injection. 
The mechanism responsible for this rise is unknown. In a 
previous study, we showed that simply exposing a rat to 
the stress of an “open-field” resulted in a rapid rise in 
plasma IL 6. 29 Possibly the stress associated with this 
symptom-producing dose of pentoxifylline contributed 
to the rise in plasma IL 6 observed in our study. Another 
possibility is that the hypothermia associated with this 
high dose of pentoxifylline may have stimulated the 
release of IL 6. The logic behind this suggestion is that if 
IL 6 is an endogenous pyrogen it might also participate 
in the regulation of body temperature during non- 
infectious states. A lowering of body temperature (per- 
haps below the thermoregulatory set-point) might trig- 
ger the release of IL 6, thus helping to restore body 
temperature to its previous level. 
The high dose of pentoxifylline also blocked most of 
the rise of plasma IL 6 activity that occurred 3 hr after 
injection of LPS. This suggests to us that pentoxifyl- 
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line’s antipyretic effect could be mediated via its effects 
on reducing plasma IL 6 activity. However, the group 
injected with the low dose of pentoxifylline and LPS had 
LPS-induced fever similar to those of rats injected with 
saline and LPS, but had attenuated increases in IL 6 
activity (see Fig. 5). These data therefore pose a 
problem for the hypothesis that plasma IL 6 is responsi- 
ble for LPS-induced fever. Either this hypothesis is 
wrong, or else it may be necessary for plasma IL 6 
activity to rise above a certain threshold (for example, 
> 100,000 U/mL) in order for fever to occur. Data 
obtained in an earlier study from this laboratory support 
this latter interpretation.25’30 However, the interpreta- 
tion of the present experiments solely in terms of IL 6 is 
made particularly difficult because pentoxifylline not 
only attenuated the rise in IL 6, a putative endogenous 
pyrogen, but also attenuated the rise in TNF, a putative 
endogenous antipyretic or cryogen in some studies’6’18 
but a putative endogenous pyrogen in others.14T’5 
The mechanism by which the plasma concentra- 
tions of IL 6 and TNF are decreased in LPS fever is not 
known. It has been reported that pentoxifylline sup- 
presses the production of LPS-induced biological3 and 
immunological4 TNF activities, which may explain the 
low level of these cytokines during LPS fever in rats 
previously treated with pentoxifylline. In addition, it is 
possible that pentoxifylline may increase the clearance 
of these cytokines from the circulation since it is a 
vasodilator and can increase arterial blood flo~.~~ 
Although many studies have indicated that TNF is 
a strong stimulator of the release of IL 6, Zabel et a1.4 
have recently shown that administration of pentoxifyl- 
line to human subjects abolished the endotoxin-induced 
rise in TNF (as measured by immunoassay) without 
affecting the rise of serum IL 6. In the discussion section 
of that paper, it is stated that there was no attenuation in 
the endotoxin-induced fever. It is possible that the 
failure to find any decrease in serum IL 6 or reduction in 
fever might be the result of the relatively low dose of 
pentoxifylline used in this human study (7-8 mg/kg). 
Overall, our data show that pentoxifylline, at least 
at a dose that appears to exert some toxicity, lowers 
normal body temperature, attenuates LPS-induced fe- 
ver, and attenuates the rise in both TNF and IL 6 in 
response to LPS. The lower dose of pentoxifylline does 
not appear to be toxic and has no detectable effect on 
either normal body temperature or the fever caused by 
LPS, but does tend to attenuate both the plasma TNF 
and IL 6 rises caused by LPS. 
MATERIALS AND METHODS 
Animals 
One hundred twelve specific-pathogen-free male Sprague- 
Dawley rats weighing 250-300 g each were obtained from 
Charles River (Portage, MI). Rats were housed at 23-25OC 
with a 12/12 hr light-dark cycle and given ad libitum tap 
water and rodent chow. 
Measurement of Body Temperature 
Core temperature was measured by biotelemetry with the 
use of transmitters implanted intraperitoneally (Mini Mitter, 
Inc., Sunriver, OR).3’ The transmitters were implanted at 
least 4 days before experiments. Each transmitter was cali- 
brated prior to implantation. Output (frequency in Hz) was 
monitored by a mounted antenna placed under each rat’s cage 
and the data fed into a peripheral processor (Dataquest III 
system, Mini Mitter, Inc.) connected to an IBM PC. Tempera- 
tures were recorded at 5 min intervals. To avoid any circadian 
variation in body temperature or plasma IL 6 activity, all 
injections of LPS and pentoxifylline were made between 8:00 
AM and 10:00 AM. 
Bioassay for IL 6 
Plasma IL 6 activity was measured using the IL 6-depen- 
dent B-9 hybridoma cell line.32-34 The B-9 cells were cultured 
in Iscove’s modified Dulbecco’s medium (IMDM; Life Tech- 
nology, Inc.) supplemented with human recombinant IL 6 
(rIL6) (10 U/mL obtained from L. Aarden), 20 uM 2-mercap- 
toethanol, 10% heat-inactivated fetal calf serum (FCS), 100 
IU/mL penicillin and 100 pg/mL streptomycin. Cells were 
washed once in the above medium without added IL 6 before 
the addition of the plasma samples or known amounts of 
human rIL 6. 
To run the IL 6 assay, a 5 ~1 sample to be assayed was 
combined with 5000 B9 cells in 195 ~1 IMDM/5% FCS in a 
flat-bottom microtiter plate (Corning) for a final volume of 
200 ~1. All samples were run in duplicate. The control medium, 
which contains no IL 6, was run in quadruplicate. In addition 
to the undiluted plasma samples, a serial dilution of each 
sample was assayed. Serial dilution was performed because 
our standard curve indicated that high levels of IL 6 inhibit 
growth of the B-9 cells. Each sample was serially diluted 
initially to a maximum of 1:62,500. If IL 6 activity was present 
at the 1:62,500 dilution, the sample was then further serially 
diluted to 1:1,562,500. 
Cells were pulsed at 68 to 72 hr with 0.5 &i of 
[3H]-thymidine and harvested onto glass fiber filter strips 
(Cambridge Technology, Inc.); the radioactivity incorporated 
into DNA was counted by a p-scintillation counter (Packard 
Instrument Company). For each assay, a standard curve was 
run with recombinant human IL 6. One unit of IL 6 is equal to 
the amount that caused half-maximum proliferation in the 
standard curve. From this standard curve, a best-fit regression 
was calculated for the rising portion of the curve in the linear 
range. The equation for this best fit line was used to calculate 
IL 6 activity in plasma samples. 
All samples were serially diluted until they become 
undetectable. All counts per minute (cpm) that fell within 2 
standard deviations of the baseline cpm were excluded to 
reduce the potential error resulting when converting from cpm 
to units of IL 6 by multiplying by the dilution factor. The 
largest calculated IL 6 activity that fell outside the 2 standard 
deviations of the baseline and fell well below the peak was 
taken as the IL 6 value. This ensured that all data used fell in 
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the steep linear portion of the standard curve, which increased 
the accuracy of the values. 
Bioassay for TNF 
The WEHI 164 subclone 13 (A. Waage, University of 
Trondheim, Norway) has been shown to be extremely useful in 
detecting low concentrations of TNF (in the picogram range).‘5 
WEHI 164 subclone 13 cells were suspended at 5 x lo4 in 100 
~1 per well of RPM1 1640, 10% fetal calf serum, 1 mM 
L-glutamine, and 0.5 Hg/mL actinomycin D in 96-well tissue 
culture plates. A serial dilution was done for each plasma 
sample to be assayed, starting from 1:20 to a maximum of 
1:40,960 then 100 ~1 of the diluted sample was added to the 
cells and incubated for 20 hr at 37’C in 5% CO,. To measure 
the percent of viable cells, the 3-(4,5-dimethylthiazol-2-yl)-2- 
5-diphenyl-tetrazolium bromide (MTT tetrazolium) cytotoxic- 
ity assay was used. Twenty microliters of MTT tetrazolium (5 
mg/mL, Sigma) was added to each well and allowed to 
incubate an additional 4 hr. To dissolve the dark blue tetra- 
zolium crystals, 150 ~1 of supernatant fluid was removed from 
each well and 100 J of isopropranol with 0.04 N HCI was 
added and allowed to react for approximately 4 hr. The plates 
were then read in a microELISA reader at 570 nm and units 
were calculated based on the values obtained with a purified 
recombinant human TNF standard (Cetus Corp., Emeryville, 
CA) tested in the same assay. The calculation of TNF activity 
was done in a manner similar to that for IL 6 (for details please 
see Bioassay of IL 6). 
Drugs 
Purified LPS (Escherichia coli endotoxin 011 l:B4, cata- 
log number L 97F-4089, Sigma) was dissolved in 0.9% sterile 
pyrogen-free sodium chloride solution (saline) and injected IP 
in doses of 10 pg/kg. 
Pentoxifylline (catalog number RC 3795, Hoechst- 
Roussel Pharmaceuticals, Inc.) was dissolved in saline and 
injected IP at a dose of 50 mg/kg or 200 mg/kg. The control 
animals were given the same volume of saline. 
Plasma Samples 
Rats were anesthetized by intramuscular injection of 
ketamine hydrochloride and Xylazine (Rompun). Blood was 
collected within 1.5 min into a heparinized syringe by cardiac 
puncture. Plasma was separated by centrifugation of the 
freshly drawn blood and stored at -20°C. 
Data Analysis 
Data are presented as mean + SE. Statistical differences 
among three group means were determined for changes in 
body temperature, plasma IL 6 activity, and TNF activity 
using one factor ANOVA, followed by pairwise comparisons 
tested by Fisher least significant difference. 
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